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Objective: Endograft mural thrombus has been associated with stent graft or limb thrombosis after endovascular aneu-
rysm repair (EVAR). This study aimed to identify clinical and morphologic determinants of endograft mural thrombus
accumulation and its inﬂuence on thromboembolic events after EVAR.
Methods: A prospectively maintained database of patients treated by EVAR at a tertiary institution from 2000 to 2012 was
analyzed. Patients treated for degenerative infrarenal abdominal aortic aneurysms and with available imaging for
thrombus analysis were considered. All measurements were performed on three-dimensional center-lumen line computed
tomography angiography (CTA) reconstructions. Patients with thrombus accumulation within the endograft’s main
body with a thickness >2 mm and an extension >25% of the main body’s circumference were included in the study group
and compared with a control group that included all remaining patients. Clinical and morphologic variables were assessed
for association with signiﬁcant thrombus accumulation within the endograft’s main body by multivariate regression
analysis. Estimates for freedom from thromboembolic events were obtained by Kaplan-Meier plots.
Results: Sixty-eight patients (16.4%) presented with endograft mural thrombus. Median follow-up time was 3.54 years
(interquartile range, 1.99-5.47 years). In-graft mural thrombus was identiﬁed on 30-day CTA in 22 patients (32.4% of the
study group), on 6-month CTA in 8 patients (11.8%), and on 1-year CTA in 17 patients (25%). Intraprosthetic thrombus
progressively accumulated during the study period in 40 patients of the study group (55.8%). Overall, 17 patients (4.1%)
presented with endograft or limb occlusions, 3 (4.4%) in the thrombus group and 14 (4.1%) in the control group (P[ .89).
Thirty-one patients (7.5%) received an aortouni-iliac (AUI) endograft. Two endograft occlusions were identiﬁed among AUI
devices (6.5%; overall, 0.5%). None of these patients showed thrombotic deposits in the main body, nor were any outﬂow
abnormalities identiﬁed on the immediately preceding CTA. Estimated freedom from thromboembolic events at 5 years was
95%inbothgroups (P[ .97).Endograft thrombusaccumulationwas associatedwith>25%proximalaneurysmneck thrombus
coverage atbaseline (odds ratio [OR], 1.9; 95% conﬁdence interval [CI], 1.1-3.3), neck length#15mm(OR,2.4; 95%CI, 1.3-
4.2), proximal neckdiameter$30mm(OR, 2.4; 95%CI, 1.3-4.6),AUI (OR, 2.2; 95%CI, 1.8-5.5), or polyester-covered stent
grafts (OR, 4.0; 95% CI, 2.2-7.3) and with main component “barrel-like” conﬁguration (OR, 6.9; 95% CI, 1.7-28.3).
Conclusions: Mural thrombus formation within the main body of the endograft is related to different endograft conﬁg-
urations, main body geometry, and device fabric but appears to have no association with the occurrence of thrombo-
embolic events over time. (J Vasc Surg 2015;61:1391-8.)The surgical management of abdominal aortic aneu- endograft occlusion are infrequent but potentially devas-
rysms (AAAs) has progressively shifted toward endovascu-
lar aneurysm repair (EVAR) as the primary treatment1 for
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://dx.doi.org/10.1016/j.jvs.2015.01.032tating complications that have limited the clinical success
of EVAR2,3 and have been associated with preceding
endograft mural thrombus accumulation.4,5 However,
the evidence for this is scarce and potentially biased.
Endograft mural thrombus formation has been detected
as early as 1 week after endograft deployment, and its course
is still not completely understood.4 Optimal management of
asymptomatic thrombotic formation within abdominal
aortic stent grafts has not been determined; although most
experts defend conservative surveillance,6 oral anticoagula-
tion therapy has also been reported.7 There is a clear need
for further evidence to support either conduct.
Our hypothesis was that thrombus accumulation within
the main body of the endograft is not associated with the
occurrence of thromboembolic events.
METHODS
We designed a retrospective case-control study based
on a prospectively maintained observational database of1391
Fig 1. Study case selection: Inclusion criteria.
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The Netherlands. The study complies with the Helsinki
statement on research ethics, and no informed consent
was required according to institutional guidelines on
research ethics.
Patients. From 2000 to 2012, EVAR was performed
in 473 patients with AAAs at the Erasmus University Med-
ical Center, Rotterdam, The Netherlands. The type of
repair offered was individualized according to anatomic
features, health status, and history of previous abdominal
surgery (hostile abdomen). The patient’s preference was
accounted for before informed consent was obtained. Pa-
tients with previous aortic surgery or without degenerative
AAAs (ie, with isolated iliac aneurysms, mycotic aneurysms,
and anastomotic or traumatic pseudoaneurysms) as well as
patients for whom a postoperative computed tomography
angiography (CTA) image could not be obtained were
not included.
Patients presenting with in-graft thrombus with a
thickness >2 mm and an extension of >25% of the main
body’s circumference on at least three consecutive 1-mm
slices in any postoperative CTA scan were included in the
thrombus group (Fig 1). For case selection, all postopera-
tive CTA images were analyzed with center-lumen line
reconstruction. The remaining patients formed the control
group. Patients who received a stent graft other than the
ones deployed in the thrombus group were also excluded
from the study for homogeneity (two patients with Power-
link [Endologix, Irvine, Calif] stent grafts).
Postoperative surveillance. Institutional follow-up
protocols have changed signiﬁcantly during the time of
the study. From the initial practice, which consisted of
contrast-enhanced CTA at 1 month, 6 months, 12 months,
and yearly thereafter, the 6-month CTA evaluation has been
reserved only for patients with a high risk of complications.
In addition and according to the treating physician’s
expectation, selected patients with an expected lower risk of
complications or with renal function impairment have beenalternatively followed up with color duplex ultrasound or
noncontrasted CT.
Data management. Baseline clinical, anatomic, and
intraoperative data were acquired at the time of surgery. All
subsequent long-term follow-up data were prospectively
obtained on outpatient visits or from the patient’s record on
regular consultation.
Image analysis and measurements. All measurements
(diameters, lengths, angles, cross-sectional area, and
volumes) were performed with semiautomatically gener-
ated center-lumen line reconstructions on a workstation
with dedicated reconstruction software (3mensio Vascular
4.2; Medical Imaging B.V., Bilthoven, The Netherlands)
and according to previous validated methodology.8 All
long-term imaging data were obtained by a single observer
with experience in image analysis (N.O.).
A centered ellipse was assumed as the most approxi-
mate form to represent the cross-sectional area of the
main body. For cross-sectional area calculation, the largest
and lesser diameters were measured, and the respective
radius was determined. Cross-sectional area was calculated
as follows: Area ¼ rA*rB*p (in which rA is the largest
radius and rB the lesser radius, and p value was rounded
to six decimal digits). For lumen reduction determination,
the difference between the cross-sectional areas of the main
body and the patent lumen was calculated at the point of
maximum thrombus accumulation.
Deﬁnitions. Reporting was done in accordance
with the guidelines of the Society for Vascular Surgery/
American Association for Vascular Surgery Ad Hoc Com-
mittee for Standardized Reporting Practices in Vascular
Surgery.9 Cardiac status was deﬁned and scored accord-
ing to the Society for Vascular Surgery/American Associ-
ation for Vascular Surgery medical comorbidity grading
system.10
Thromboembolic eventsweredeﬁnedas the compositeof
endograft occlusion, iliac limb occlusion, thromboembolic
acute limb ischemia, and blue toe syndrome. Oversizing was
determined from the ratio between the implanted main
body diameter and the reference neck diameter in the ﬁrst
15 mm of the infrarenal aneurysm neck. Neck length was
deﬁned as the distance between the distal point of the lower-
most renal artery ostium and the beginning of the aneurysm.
Variation of the main body cross-sectional area was
deﬁned in percentage from the ratio between the maximum
cross-sectional area assumed by the main body of the endo-
prosthesis and the minimum main body cross-sectional area
identiﬁed in the ﬁrst 10 mm of the stent graft.
End points. The primary end point of this study was
freedom from thromboembolic events. In addition, clinical
and morphologic variables were explored for association
with signiﬁcant thrombus accumulation within the endograft.
Statistical analysis. Categorical variables are presented
as count and percentage and were compared by the Pearson
c2 test. Continuous variables are presented as mean and stan-
dard deviation or median and interquartile range. Differences
between groups were analyzed by the Mann-Whitney U test
for independent nonparametric data and the Student t-test





(n ¼ 346) P value OR (95% CI)
Age $70 years 34 (50.0) 231 (66.8) .008 0.50 (0.29-0.84)
Male gender 59 (86.8) 312 (90.2) .400 d
Previous history of or continuous smoking
at time of implantationa
49 (77.8) 221 (69.1) .166 d
Cardiac status $2b 14 (20.6) 62 (17.9) .563 d
Hypertension 48 (70.6) 217 (62.7) .338 d
Cancerc 11 (20.0) 56 (18.7) .816 d
ASA class 3/4 34 (50.0) 165 (47.7) .738 d
Single antiplatelet therapy at time of implantation 61 (88.7) 289 (83.5) .215
Dual antiplatelet therapy at time of implantation 1 (1.5) 6 (1.7)
Oral anticoagulation at time of implantationd 7 (10.3) 50 (15.4) .278 0.63 (0.27-1.46)
Elective EVAR 56 (82.4) 270 (78) .426 d
AAA Ø, mm 61 (54.0-74.3) 60 (55.0-72.3) .497 d
AAA volume, mL 190.0 (150.8-369.0) 188.0 (143.0-281.0) .595 d
Aneurysm growth $5 mm 10 (14.7) 50 (14.6) .978
Neck thrombus >25% 26 (38.2) 94 (27.2) .016 1.98 (1.21-3.24)
Neck calciﬁcation >25% 19 (27.9) 65 (18.9) .089 1.67 (0.93-3.04)
Proximal neck length #15 mm 21 (30.9) 55 (15.9) .004 2.36 (1.31-4.26)
Proximal neck Ø $30 mm 15 (22.1) 42 (12.1) .030 2.05 (1.06-3.96)
a Angle, degrees 20.0 (10.25-36.8) 21.0 (12.0-34.8) .782 d
b Angle, degrees 34.0 (19.3-53.3) 35.0 (23.0-53.8) .141 d
AUI graft conﬁguration 10 (14.7) 21 (6.1) .014 2.66 (1.19-5.94)
Main body diameter $31 mm 32 (54.2) 104 (33.1) .002 2.39 (1.36-4.20)
Endograft fabric, polyester 49 (72.1) 186(53.8) .005 2.22 (1.25-3.92)
Ratio between cross-sectional areas of
main body and limbs $2.3
42 (61.8) 136 (39.4) .001 1.93(1.14-3.29)
Main body cross-sectional area variation $50%e 9 (13.2) 23 (6.6) .063 2.14 (0.94-4.86)
Distal landing zone in the EIA 26 (38.2) 92 (26.6) .052 1.71 (0.99-2.95)
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; AUI, aortouni-iliac; CI, conﬁdence interval; EIA, external iliac artery; EVAR,
endovascular aneurysm repair; OR, odds ratio.
Continuous data are presented as mean 6 standard deviation or median (interquartile range) and categorical data as count (percentage).
aUnavailable data for 31 patients (7.5%).
bAccording to the Society for Vascular Surgery/American Association for Vascular Surgery medical comorbidity grading system.
cUnavailable data for 59 patients (14.9%).
dUnavailable data for 21 patients (5.1%).
eMeasured between cross-sectional area at the start of the ﬁrst covered stent and maximum cross-sectional area of the endograft main body.
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ables with normal distributions. Survival curves for freedom
from thromboembolic eventswere estimated byKaplan-Meier
methods, and equality was tested with the Mantel-Cox log-
rank test. Multivariate logistic regression was performed to
assess independent association between endograft mural
thrombus accumulation and signiﬁcant variables determined
by univariate analysis. Conﬁdence intervals (CIs) of 95% were
used, and statistical signiﬁcance was considered if P < .05. All
statistical analysis was performed with Statistical Package for
Social Sciences (SPSS) 21.0 (IBM Inc, Chicago, Ill).
RESULTS
Among the 473 AAA patients submitted to EVAR at
our institution from 2000 to 2012, 414 fulﬁlled the inclu-
sion criteria. Mean age was 71.8 (69.0) years; 371 (89.6%)
were men. Sixty-eight patients presenting with intrapros-
thetic mural thrombus were included in the study group,
and the remaining 346 were considered controls. Baseline
characteristics are depicted in Table I.
Median follow-up was 3.54 years (1.99-5.47) and did
not differ between groups (thrombus group, 3.99 years[2.26-3.41]; no-thrombus group, 3.44 years [1.80-5.37];
P ¼ .107).
Median time at diagnosis of mural thrombotic deposi-
tion was 12.0 months (1.2-23.0 months) in the thrombus
group (N ¼ 68). Substantial mural thrombus was identiﬁed
on 30-day CTA in 22 patients (32.4%), 6-month CTA in 8
patients (11.8%), 1-year CTA in 17 patients (25%), 2-year
CTA in 9 patients (13.2%), and 3-year CTA or after in 12
patients (17.6%).
Thromboembolic events. Seventeen patients (4.1%)
presented with thromboembolic events after a median
time of 15.0 months (6.0-23.8). Main body occlusions
were reported in two patients in the control group (0.5%
overall), both aortouni-iliac (AUI) devices. None of these
patients showed thrombotic deposits in the main body, nor
were any runoff abnormalities noted on the immediately
preceding CTA, performed 2 months earlier in both cases.
In one patient, the endograft occlusion had been preceded
1 year before by a stent graft migration that had been treated
with an AUI conversion. This patient ultimately underwent
an axillary-bifemoral bypass. The second patient was treated
primarily for a ruptured AAA with an AUI stent graft, which
Fig 2. Kaplan-Meier survival estimates for freedom from composite
end point of endograft or limb occlusion and acute limb ischemia.
EVAR, Endovascular aneurysm repair; SE, standard error.
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thrombolysis followed by surgical thrombectomy.
Thromboembolic events including device occlusion, iliac
limb occlusions, acute limb ischemia, and blue toe syndrome
occurred in 3 patients (4.4%) with signiﬁcant mural thrombus
and in 12 patients (3.5%) of the no-thrombus group (P¼ .70).
Thirteen patients were treated with catheter-directed throm-
bolysis, followed by iliac percutaneous transluminal angio-
plasty in six patients, limb extensions in three patients,
surgical thrombectomy in two patients, and a femoral-
femoral crossover in one patient. The remaining two patients
had no signiﬁcant symptoms and remained untreated. None
of the reported patients underwent major amputations. The
estimated freedom from thromboembolic events at 2 and
5 years was 95% in the thrombus group; in the no-thrombus
group, it was 96% and 95% (P ¼ .97) (Fig 2).
Clinical variables. Overall, 62 patients (91.2%) in the
study group and 295 patients (85.3%) in the control group
were receiving antiplatelet therapy at the time of implanta-
tion (P ¼ .215; Table I). Regarding oral anticoagulation
therapy, there were 7 patients (10.3%) in the study group
and 50 (15.4%) in the control group receiving this therapy
at the time of implantation (P ¼ .24). Oral anticoagulation
at the time of implantation was found not to be a signiﬁ-
cant protection factor against in-graft thrombus accumu-
lation on univariate regression analysis (hazard ratio, 0.63;
95% CI, 0.27-1.46).
In regard to previous or concurrent tobacco abuse at
the time of implantation, the study group did not differ
signiﬁcantly from the controls (P ¼ .166; Table I).
Morphologic characteristics. Median AAA diameter
at baseline was 60.0 mm (55.0-72.0 mm) and did not
differ signiﬁcantly between groups (P ¼ .5; Table I).
Aneurysm growth $5 mm was identiﬁed in 10 patients in
the study group (14.7%) and in 50 in the control group
(14.6%) (P ¼ .978).Patients with shorter proximal aortic necks (#15 mm)
at baseline presented higher odds of thrombus formation
(odds ratio [OR], 2.4; 95% CI, 1.3-4.2; Table II). Overall
median native aortic neck diameter at baseline was signiﬁ-
cantly larger in the study group (P ¼ .03). Patients with
preoperative neck diameters $30 mm presented higher
odds of endograft mural thrombus buildup (OR, 2.4;
95% CI, 1.3-4.6).
Proximal native neck thrombus coverage at baseline of
>25% occurred in 26 patients (38.2%) in the study group
and in 94 patients (27.2%) in the control group (P ¼
.016). On multivariate analysis, baseline proximal aneurysm
neck thrombus was an independent predictor of in-graft
thrombus development (OR, 1.9; 95% CI, 1.1-3.3).
In the study group, thrombus extended into the iliac
limbs in 15 patients (22.1%); in the control group, focal
thrombus deposits were identiﬁed in 24 cases (6.9%) within
the iliac limbs (P< .001). In regard to the iliac arteries, iliac
stenosis was identiﬁed in 1 patient (1.5%) in the thrombus
group and in 10 patients (2.9%; P ¼ .51) in the control
group (patent lumen, >7 mm; extension, <3 cm). The
external iliac artery was one of the distal landing zones in
26 patients (22%) in the study group and in 42 patients
(14.2%) in the control group (P ¼ .052) but was not found
to be an independent predictor of main body thrombus for-
mation in multivariate analysis (Table II). Bilateral external
iliac landing in bifurcated devices or external iliac landing of
AUI devices was separately assessed for association with
in-graft thrombus accumulation but was also statistically
not signiﬁcant in univariable analysis (P ¼ .816).
Thrombus dynamics. First thrombotic deposits were
identiﬁed among the study group on 30-day CTA in 22
patients (32.4%), 6-month CTA in 8 patients (11.8%), 1-
year CTA in 17 patients (25%), 2-year CTA in 9 patients
(13.2%), and 3-year CTA or after in 12 patients (17.6%).
Forty-four of these patients (64.7%) had undergone more
than one CTA evaluation during follow-up. Mean variation of
the maximum thickness was 3.3 mm (65.01) and ranged
from 3.20 to þ29.5 mm. Partial thrombus regression was
identiﬁed in four patients (9.1%), ranging from 0.40
to 3.20 mm in maximum thickness. Complete resolution
was not identiﬁed, and of these four patients, only two were
taking anticoagulants. The remaining 40 patients from this
subgroup (58.8% of the study group) all demonstrated pro-
gressive thrombus accumulation from the ﬁrst positive postop-
erative CTA scan for mural thrombus until the last CTA scan
available (Fig 3). At the last CTA scan available, median lumen
reduction by mural thrombosis in the study group was 33.2%
and ranged from 12.7% to 78.5%.
Device-related features. Deployed devices differed
signiﬁcantly among groups (P ¼ .007). Overall, Endurant
(Medtronic, Santa Rosa, Calif) stent grafts were implanted in
190 patients (45.9%); Excluder Low-Permeability devices
(W. L. Gore & Associates, Flagstaff, Ariz), in 124 (30.0%);
Excluder stent grafts (original device), in 55 (13.3%); Zenith
endografts (Cook, Bloomington, Ind), in 25 (6%); Talent
devices (Medtronic), in 16 (3.0%); and LifePath System
(McKinney, Tex) balloon-expandable endografts, in 4 (1.0%).
Table II. Multivariate analysis for in-graft thrombus
accumulation
Multivariate analysis
OR 95% CI P value
Clinical variables
Age $70 years 0.81 0.49-1.37 .429
Morphologic variables
Neck thrombus $25% 1.90 1.10-3.31 .020
Neck calciﬁcation $25% 1.66 0.90-3.07 .105
Neck length #15 mm 2.35 1.31-4.23 .004
Neck diameter $30 mm 2.39 1.25-4.58 .008
Device-related variables
AUI graft conﬁguration 2.20 1.88-5.49 .050
Polyester fabric 3.98 2.17-7-29 <.001
Ratio between cross-sectional
areas of main body
and limbs $2.3
1.17 0.68-2.02 .576
Variation of main body
cross-sectional area $50%
6.92 1.69-28.31 .007
Distal landing zone EIA 1.24 0.67-2.30 .495
AUI, Aortouni-iliac; CI, conﬁdence interval; EIA, external iliac artery; OR,
odds ratio.
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study group (14.7%) and in 21 controls (6.1%). AUI
conﬁguration was found to account for a 2.2-fold odds in-
crease of in-graft thrombotic deposition (95% CI, 1.9-5.5;
Table II). As referred to previously, both device occlusions
occurred in AUI devices, but none had been preceded by
intraprosthetic thrombotic deposits.
In our population, polyester-coated devices (Endurant,
Zenith, Talent, and LifePath devices) were more prone to
building up signiﬁcant thrombus (OR, 4.0; 95% CI, 2.2-
7.3). Six-month estimates for freedom from in-graft
thrombus were 77% for polyester-based AUI endografts,
92% for polyester-covered aortobi-iliac endografts, and
96% for expanded polytetraﬂuoroethylene-covered aor-
tobi-iliac endografts. At 18 months, the estimated freedom
from thrombus formation was 67%, 81%, and 92%, respec-
tively (P < .001) (Fig 4). Increased endograft thrombus
accumulation was found in cases of “barrel-like” conﬁgura-
tion of the main component (Fig 5) with a cross-sectional
area increase $50% throughout the main body (OR, 6.9;
95% CI, 1.7-28.3; Table II).
Thrombus formation within the iliac limbs was identiﬁed
in 10 (19.6%) of the patients with bell-bottom ($24mm) iliac
extensions and in 29 (8%) of those without (P¼ .008). Depo-
sition of thrombus within the main body was not signiﬁcantly
different among patients with large ($20 mm) (P ¼ .35) or
bell-bottom ($24 mm) iliac limbs (P ¼ .34).
DISCUSSION
Development of signiﬁcant mural thrombus has cast
uncertainty on long-term outcomes after EVAR, and
several mechanisms have been proposed to explain its for-
mation. We provide the largest study assessing the clinical
impact of mural thrombus formation within the main
body of abdominal aortic endografts and identify clinical,morphologic, and device-related risk factors for its develop-
ment. This information was obtained in a large population
of EVAR patients with long-term follow-up and adds new
insights into the mechanisms of mural thrombus accumula-
tion within the main component of abdominal aortic
endografts. Although a frequent event, in our population,
endograft mural thrombus formation was not associated
with thromboembolic events during follow-up. Endograft
characteristics such as conﬁguration, fabric, and main
body geometry were found to be distinctly associated
with the appearance of in-graft thrombus.
Endograft mural thrombosis is a common event in
abdominal aortic endografts, with reported rates ranging
from 19% to 33%,6,11,12 but it has also been reported in
thoracic aortic stent grafts.13,14 Whether in-graft mural
thrombus predicts future limb or endoprosthesis occlusion
in the long term has remained unresolved.4 Moreover,
different strategies have been suggested after diagnosis,
including intensiﬁcation of surveillance and even oral anti-
coagulation.7 Mestres et al5 reported an association be-
tween endograft mural thrombotic deposits and device
occlusion during a follow-up period of 24 months (P ¼
.003). In contrast, in our population, an increased propen-
sity of graft or limb occlusions among the study group was
not identiﬁed. In addition, limb occlusions did not occur
preferentially among patients with thrombus accumulation
within the endograft’s main body, nor were those events
preceded by thrombus deposition on the immediately pre-
ceding CTA scan. Indeed, limb occlusion may be related to
kinking or the presence of iliac lesions with hemodynamic
impact, as pointed out by van Zeggeren et al.15 Therefore,
our results suggest that neither an interventional attitude
nor an intensiﬁcation of postoperative imaging is warranted
in patients presenting with in-graft mural thrombus.
Thrombus accumulation within the endograft seems to
be a dynamic phenomenon. Cases of partial regression
were identiﬁed among our study group, but we did not
identify complete resolution as reported elsewhere.4 This
discrepancy may be explained by our inclusion criteria,
which selected patients with signiﬁcant thrombus load
within the endograft, and the follow-up time. Although
only a small proportion of our population was receiving
oral anticoagulation, it was not found to be protective
against endograft thrombus accumulation, as reported
also by Wu et al,16 or to induce thrombus regression
among the study group.
In-graft thrombus accumulation is a multifactorial pro-
cess, resulting from the complex interaction of systemic and
local hemodynamic factors, hemorheologic properties, and
endograft characteristics. Smoking is associated with a sus-
tained low-grade systemic inﬂammatory response and pro-
duces an imbalance of rheologic, coagulation, and
endothelial functions.17 The consequent increase in blood
viscosity18 has been demonstrated to modify wall shear
stress.19 However, in our sample, we could not relate
thrombus accumulation to smoking habits.
Mestres et al5 proposed that mural thrombus of the
aneurysmatic native aorta might lead to incomplete
Fig 4. Kaplan-Meier survival estimates for freedom from mural
thrombus comparing different combinations of endograft conﬁg-
uration and fabric. ABI, Aortobi-iliac; AUI, aortouni-iliac; ePTFE,
expanded polytetraﬂuoroethylene; EVAR, endovascular aneurysm
repair; SE, standard error.
Fig 3. Thrombus thickness variation. Subgroup analysis of pa-
tients in the study group with more than one postoperative
computed tomography angiography (CTA) scan (n ¼ 44) during a
median follow-up of 3.54 years (1.99-5.47). Measurements were
performed using the last available and ﬁrst postoperative CTA
scans.
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generation of turbulent ﬂow, which might predict endog-
raft thrombus formation. However, as demonstrated by
Bastos Gonçalves et al,20 after stent graft implantation,
aneurysm neck thrombus progressively reduces over time
and ultimately disappears. Moreover, in a signiﬁcant pro-
portion of our study group, thrombus reappeared intralu-
minally within the device during follow-up, similar to
Houdini’s famous “walking through a brick wall” illusion.
We hypothesize that in addition to device-related factors,
hemorheologic and hemodynamic factors may also play a
role in this “Houdini effect.”
Abdominal aortic blood ﬂow patterns are complex,
differing signiﬁcantly according to the physiologic state.21-23
Local morphologic features such as angulation24 and aortic
arch-generated vortical ﬂow patterns may also inﬂuence wall
shear stress and blood stasis.25,26 Endograft implantation
may further modify these ﬂow patterns,27,28 which may in
part contribute to the consistently reported reduced time
elapsed until detection of the ﬁrst in-graft thrombotic de-
posits.4,5,11,16 Our study group also demonstrated such ﬁnd-
ings. Chong et al29 demonstrated in vitro that proximal
aneurysm neck angulation may produce complex turbulent
ﬂow and recirculation patternswithin abdominal aortic endog-
rafts.However, in our population, wewere not able to demon-
strate this association.
Endograft features seem to play a role in the develop-
ment of in-graft thrombus. Wu et al16 correlated intrapros-
thetic thrombus development with a speciﬁc device (the
Zenith endograft). However, more important, stent graft
conﬁguration30 and main body geometric conﬁguration
may be the factors responsible for in-graft thrombus forma-
tion, leading to modiﬁed ﬂow conditions within the device
and to thrombus accumulation.6,31 Wu et al also correlatedthrombus development to ﬂow deceleration (“plug ﬂow”)
within the device. Accordingly, this hemodynamic condi-
tion seems to be produced by sharp cross-sectional area
decreases, such as in AUI devices or in stent graft exten-
sion to the external iliac arteries. In our population,
both AUI conﬁguration and an increased ratio between
main body and cumulative limb cross-sectional areas
were associated with an increased risk of endograft mural
thrombosis in univariable analysis, which is in accordance
with other reports.5 However, we hypothesized that the
higher prevalence of AUI stent grafts among the study
group might contribute greatly to this ﬁnding, and in cor-
recting for this factor, unlike in the study of Wu et al,16 a
higher ratio between the cross-sectional areas of main
body and limbs and distal landing in the external iliac
artery were not found to be independent predictors of
thrombus accumulation.
Our results suggest that along with device conﬁgura-
tion, a geometric barrel-like conﬁguration of the main
component after endograft deployment may also play a
role. This event may be more pronounced in devices
with larger diameters and in patients with shorter neck
lengths, thus restraining less the endograft’s full expan-
sion to its diameter. Consequently, decreased ﬂow
Fig 5. Midsection dilation of the main body component with
thrombus formation. The dashed lines and arrows demonstrate the
barrel-like conﬁguration of the main component within the
aneurysm sac.
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raft lumen can lead to subsequent thrombus accumula-
tion.16 In our study, patients receiving larger devices
and with shorter proximal necks presented more
frequently with endograft thrombus. In addition, midsec-
tion dilation of the main component (barrel-like conﬁgu-
ration) was also found to be an independent predictor of
signiﬁcant endograft thrombus lining. The same mecha-
nism can also explain the similar phenomenon among
patients with bell-bottom iliac extensions in our study,
which was statistically signiﬁcant.
Device fabric may also play a role in mural thrombus
accumulation. Polyester has been reported to be more
thrombogenic than others fabrics.32,33 In line with the
ﬁndings of other authors,5,6 we also identiﬁed an increased
risk of intraprosthetic thrombus accumulation in patients
receiving polyester-covered devices.
The method of thrombus assessment chosen may be
pointed out as a drawback in our study. Thrombus-
covered circumference has been preferentially used in
studies reporting on mural thrombus within the native
aorta.10,34-37 However, this method does not inform on
the thickness or the degree of lumen reduction caused by
the thrombotic accumulation. Quantitative methods as re-
ported by Wyss et al,38 although providing overall quanti-
ﬁcation, fail to inform also on circumferential involvement
or degree of lumen restriction, as the latter also depends onthe distribution of thrombus within the endoprosthesis and
its dimensions. Our selection criteria included both the
circumferential coverage of the endograft’s main body sur-
face by thrombus and its maximum thickness in part to
overcome these limitations. Furthermore, unlike other
reports that resorted to nondedicated imaging software5
or did not also provide circumferential or quantitative
assessments,4,6,16 we provide maximum lumen reduction
by thrombus formation calculated from reproducible mea-
surements performed on dedicated imaging software.
Other limitations that can be noted are the retrospective
design of our study, thus making data about the compli-
ance of patients with antiplatelet therapy after EVAR and
the duration of oral anticoagulation irretrievable. Also, his-
topathologic conﬁrmation of the thrombus was not per-
formed. However, we chose signiﬁcant thrombus
thickness and circumferential coverage thresholds for the
selection of the thrombus group to exclude patients with
focal thrombus or ﬁbrin accumulation. Importantly, our
results must be interpreted with caution in light of the
limited follow-up period of our studied population, and
therefore subsequent investigation is warranted to further
assess the clinical signiﬁcance of intraprosthetic thrombus
after EVAR. Finally, our conclusions may not apply to
endografts deployed in other anatomic locations, but
further investigation is warranted.
CONCLUSIONS
This study suggests that development of thrombotic de-
posits within the main body of an abdominal aortic endo-
prosthesis is not associated with endograft or limb
thrombosis. Consequently, a conservative approach may
be followed in patients with asymptomatic intraprosthetic
thrombus accumulation during themidterm. Long-term re-
sults are still necessary to determine the safety of watchful
waiting in these cases. In regard to surveillance, our ﬁndings
do not support an intensiﬁcation of the imaging protocol in
patients with uneventful mural thrombus formation within
abdominal stent grafts. In addition, oral anticoagulation
did not decrease the odds for development of signiﬁcant
thrombus within abdominal aortic endografts. In our study,
signiﬁcant endograft thrombus deposition was indepen-
dently associated with baseline thrombus load in the prox-
imal aneurysm neck, proximal neck diameter, AUI
endograft conﬁguration, and polyester fabric.
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